Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 6, 2022- The company announced it's developing a new category of consumer biowearables called Lingo, which is being designed to track key signals in the body - such as glucose, ketones, and lactate - to help people better understand their general health and take action- Abbott is the first healthcare company to headline the Consumer Electronics Show, with Chairman and CEO Robert Ford presenting alongside scientists and inventors, industry partners, influencers and people who use Abbott health tech- Jan 4, 2022- New U.S. FDA-approved labeling lifts restrictions on 60-centimeter Octrode™ leads, which are implanted, electrically insulated wires that transmit electrical impulses to the target nerves- Expanded MRI compatibility allows more patients to obtain necessary scans and increases efficiencies for radiologists
- Nov 15, 2021- Abbott included on DJSI for 17 consecutive years for strong environmental, social and governance (ESG) performance- Top score in the Health Care Equipment & Supplies sector reflects Abbott's 2030 Sustainability Plan focus on innovating for greater access to life-changing technologies and breaking down barriers to health equity
- Nov 12, 2021-- New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms-- Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed-- Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval